These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 22356636)

  • 1. The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives.
    Burden AD; Warren RB; Kleyn CE; McElhone K; Smith CH; Reynolds NJ; Ormerod AD; Griffiths CE;
    Br J Dermatol; 2012 Mar; 166(3):545-54. PubMed ID: 22356636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register.
    Iskandar IY; Ashcroft DM; Warren RB; Yiu ZZ; McElhone K; Lunt M; Barker JN; Burden AD; Ormerod AD; Reynolds NJ; Smith CH; Griffiths CE
    Br J Dermatol; 2015 Aug; 173(2):510-8. PubMed ID: 25989336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
    Yiu ZZN; Ashcroft DM; Evans I; McElhone K; Lunt M; Smith CH; Walton S; Murphy R; Reynolds NJ; Ormerod AD; Griffiths CEM; Warren RB;
    Br J Dermatol; 2019 Feb; 180(2):329-337. PubMed ID: 30070708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
    Alabas OA; Mason KJ; Yiu ZZN; Warren RB; Dand N; Barker JN; Smith CH; Griffiths CEM;
    Br J Dermatol; 2024 Apr; 190(5):689-700. PubMed ID: 38051972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
    Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
    JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
    Warren RB; Smith CH; Yiu ZZN; Ashcroft DM; Barker JNWN; Burden AD; Lunt M; McElhone K; Ormerod AD; Owen CM; Reynolds NJ; Griffiths CEM
    J Invest Dermatol; 2015 Nov; 135(11):2632-2640. PubMed ID: 26053050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland.
    Garcia-Doval I; Descalzo MA; Mason KJ; Cohen AD; Ormerod AD; Gómez-García FJ; Cazzaniga S; Feldhamer I; Ali H; Herrera-Acosta E; Griffiths CEM; Stern RS; Naldi L;
    Br J Dermatol; 2018 Oct; 179(4):863-871. PubMed ID: 29723914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
    Iskandar IYK; Ashcroft DM; Warren RB; Evans I; McElhone K; Owen CM; Burden AD; Smith CH; Reynolds NJ; Griffiths CEM
    Br J Dermatol; 2017 May; 176(5):1297-1307. PubMed ID: 27589476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
    Iskandar IYK; Warren RB; Lunt M; Mason KJ; Evans I; McElhone K; Smith CH; Reynolds NJ; Ashcroft DM; Griffiths CEM;
    J Invest Dermatol; 2018 Apr; 138(4):775-784. PubMed ID: 29080680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy.
    Yiu ZZN; Sorbe C; Lunt M; Rustenbach SJ; Kühl L; Augustin M; Mason KJ; Ashcroft DM; Griffiths CEM; Warren RB;
    Br J Dermatol; 2019 Apr; 180(4):894-901. PubMed ID: 30430546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR.
    Alabas OA; Mason KJ; Yiu ZZN; Hampton PJ; Reynolds NJ; Owen CM; Bewley A; Laws PM; Warren RB; Lunt M; Smith CH; Griffiths CEM;
    Br J Dermatol; 2023 Apr; 188(5):618-627. PubMed ID: 36763783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
    Yiu ZZN; Mason KJ; Hampton PJ; Reynolds NJ; Smith CH; Lunt M; Griffiths CEM; Warren RB;
    Br J Dermatol; 2020 Aug; 183(2):294-302. PubMed ID: 32124442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
    Alabas OA; Mason KJ; Yiu ZZN; Warren RB; Lunt M; Smith CH; Griffiths CEM;
    Br J Dermatol; 2023 Aug; 189(3):271-278. PubMed ID: 37226927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
    Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
    J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Side effects of biologic therapies in psoriasis].
    Altenburg A; Augustin M; Zouboulis CC
    Hautarzt; 2018 Apr; 69(4):290-297. PubMed ID: 29568996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR).
    Mahil SK; Wilson N; Dand N; Reynolds NJ; Griffiths CEM; Emsley R; Marsden A; Evans I; Warren RB; Stocken D; Barker JN; Burden AD; Smith CH;
    Br J Dermatol; 2020 May; 182(5):1158-1166. PubMed ID: 31286471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register.
    Yiu ZZN; Mason KJ; Hampton PJ; Reynolds NJ; Smith CH; Lunt M; Griffiths CEM; Warren RB;
    JAMA Dermatol; 2021 Jan; 157(1):66-73. PubMed ID: 33263718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm.
    Belinchón I; Ramos JM; Carretero G; Ferrándiz C; Rivera R; Daudén E; De la Cueva-Dobao P; Gómez-García FJ; Herrera-Ceballos E; Sánchez-Carazo JL; López-Estebaranz JL; Alsina M; Ferrán M; Torrado R; Carrascosa JM; Llamas-Velasco M; Ortiz PL; García-Doval I; Descalzo MA;
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1700-1708. PubMed ID: 28485816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest.
    Reich K; Mrowietz U; Radtke MA; Thaci D; Rustenbach SJ; Spehr C; Augustin M
    Arch Dermatol Res; 2015 Dec; 307(10):875-83. PubMed ID: 26358263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety profile of biologic drugs for psoriasis in clinical practice: An Italian prospective pharmacovigilance study.
    Iannone LF; Bennardo L; Palleria C; Roberti R; De Sarro C; Naturale MD; Dastoli S; Donato L; Manti A; Valenti G; D'Amico D; D'Attola S; De Francesco AE; Bosco V; Donato Di Paola E; Nisticò SP; Citraro R; Russo E; De Sarro G
    PLoS One; 2020; 15(11):e0241575. PubMed ID: 33141869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.